LIA;TKA: Evaluation of the Effect of Triamcinolone at Different Doses on LIA During TKA

Sponsor
Peking University Third Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05997238
Collaborator
(none)
90
1
11.2
8

Study Details

Study Description

Brief Summary

To evaluate the efficacy and safety of different doses of triamcinolone for local infiltration analgesia during total knee replacement

Condition or Disease Intervention/Treatment Phase
  • Drug: 80mg triamcinolone
  • Drug: 40mg triamcinolone

Detailed Description

Participants were enrolled according to protocol requirements. Patients who meet all inclusion criteria and do not have any exclusion criteria will be considered for inclusion in the study and will provide the relevant information used orally and in writing. Patients were divided into two groups according to the dose of triamcinolone in the peripheral infiltrating anesthetic preparation. All of which are appropriate for their surgical treatment, and the purpose of the study is to determine which formula is clinically better. All patients enrolled in this study were voluntary participants and signed informed consent. On the day of the surgery, the anesthesiologist prepares a mixture of medications based on patient groups, which are then handed to the operating room nurse. The timing, dose, and site of injection were consistent. Before the prosthesis is installed, the mixture is injected into the upper part of the patella, the posterior joint capsule, and the patellar tendon. After the prosthesis was installed, the mixture was injected into the lateral joint capsule and subcutaneous tissue. The patient, the rehabilitation physician, and the ward nurse did not know the type of mixed drug preparation injected by the patient.

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Evaluation of the Effect of Triamcinolone at Different Doses on Local Infiltration Anesthesia During Total Knee Arthroplasty
Actual Study Start Date :
Apr 25, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
low-dose triamcinolone group

add 40mg triamcinolone to the LIA preparation

Drug: 40mg triamcinolone
40mg triamcinolone was added to the preparation

high-dose triamcinolone group

add 80mg triamcinolone to the LIA preparation

Drug: 80mg triamcinolone
80mg triamcinolone was added to the preparation

Outcome Measures

Primary Outcome Measures

  1. Knee range of motion [Postoperative day 1]

    The rehabilitation doctor takes the measurements of changes in knee joint motion during the first three days after surgery

  2. Knee range of motion [Postoperative day 2]

    The rehabilitation doctor takes the measurements of changes in knee joint motion during the first three days after surgery

  3. Knee range of motion [Postoperative day 3]

    The rehabilitation doctor takes the measurements of changes in knee joint motion during the first three days after surgery

Secondary Outcome Measures

  1. Blood routine [Postoperative day 1]

    Assay index

  2. Blood routine [Postoperative day 2]

    Assay index

  3. Blood routine [Postoperative day 3]

    Assay index

  4. Test index of drainage liquefaction [Postoperative day 1]

    Assay index

  5. Complication rate [Three months after surgery]

    Follow-up visit

  6. The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index [Three months after surgery]

    The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index; range from 0 to 100; A higher score indicates better knee function

  7. Morphine intake in 48 hours after surgery [48 hours after surgery]

    The patient's use of additional analgesic drugs was recorded through the doctor's order system and converted to morphine equivalent

  8. pain visual analogue scale score [2 hours after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  9. pain visual analogue scale score [4 hours after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  10. pain visual analogue scale score [8 hours after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  11. pain visual analogue scale score [24 hours after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  12. pain visual analogue scale score [48 hours after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  13. pain visual analogue scale score [72 hours after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  14. pain visual analogue scale score [2 weeks after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  15. pain visual analogue scale score [4 weeks after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  16. pain visual analogue scale score [8 weeks after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

  17. pain visual analogue scale score [12 weeks after surgery]

    pain visual analogue scale score; range from 0 to 10; The lower it is, the better the analgesic effect

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. age in the range of 50 to 85 years old

  2. patients with knee osteoarthritis requiring primary unilateral total knee replacement

  3. the body mass index in the range of 18 to 36 kg/m2

  4. possess the physical status I-III of American Society of Anesthesiologists

  5. the patient and his family members agree and sign the informed consent

Exclusion Criteria:
  1. Non-osteoarthritis (rheumatoid arthritis, traumatic arthritis, septicemic arthritis, etc.)

  2. History of knee surgery or knee injury, such as high tibial osteotomy, meniscus repair, ligament reconstruction, etc

  3. Flexion deformity ≥30°, internal and external varus deformity ≥15°

  4. People allergic to the drugs used in this study

  5. Patients who had used glucocorticoids within 3 months before surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University Third Hospital Beijing Beijing China 100181

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

  • Study Chair: Tian Hua, doctor, Director

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT05997238
Other Study ID Numbers:
  • Triamcinolone68480
First Posted:
Aug 18, 2023
Last Update Posted:
Aug 18, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peking University Third Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2023